BeOne Medicines (NASDAQ:ONC) Insider Titus Ball Sells 136 Shares

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) insider Titus Ball sold 136 shares of BeOne Medicines stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $271.33, for a total transaction of $36,900.88. Following the completion of the sale, the insider owned 36 shares of the company’s stock, valued at $9,767.88. This trade represents a 79.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

BeOne Medicines Stock Performance

ONC traded down $4.56 during trading on Wednesday, reaching $263.61. 291,079 shares of the company’s stock were exchanged, compared to its average volume of 255,249. BeOne Medicines Ltd. – Sponsored ADR has a 1 year low of $239.25 and a 1 year high of $385.22. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.64 and a quick ratio of 3.27. The stock has a market capitalization of $28.92 billion, a P/E ratio of 58.97 and a beta of 0.49. The company’s fifty day simple moving average is $301.03 and its 200-day simple moving average is $315.60.

BeOne Medicines (NASDAQ:ONC) last posted its quarterly earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share (EPS) for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. The company had revenue of $1.51 billion during the quarter. As a group, research analysts predict that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BeOne Medicines

A number of large investors have recently bought and sold shares of ONC. Mariner LLC boosted its position in BeOne Medicines by 3.8% during the fourth quarter. Mariner LLC now owns 883 shares of the company’s stock worth $269,000 after purchasing an additional 32 shares in the last quarter. Signaturefd LLC increased its position in shares of BeOne Medicines by 10.7% in the fourth quarter. Signaturefd LLC now owns 340 shares of the company’s stock valued at $103,000 after buying an additional 33 shares in the last quarter. Farther Finance Advisors LLC raised its stake in shares of BeOne Medicines by 21.8% during the 4th quarter. Farther Finance Advisors LLC now owns 218 shares of the company’s stock worth $66,000 after buying an additional 39 shares during the period. CWM LLC raised its stake in shares of BeOne Medicines by 32.8% during the 4th quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after buying an additional 39 shares during the period. Finally, Benjamin Edwards Inc. lifted its position in shares of BeOne Medicines by 8.0% during the 4th quarter. Benjamin Edwards Inc. now owns 690 shares of the company’s stock valued at $210,000 after buying an additional 51 shares in the last quarter. Institutional investors and hedge funds own 48.55% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on ONC. Weiss Ratings reissued a “sell (d-)” rating on shares of BeOne Medicines in a research report on Monday, April 20th. Wall Street Zen raised shares of BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Wells Fargo & Company initiated coverage on shares of BeOne Medicines in a research report on Monday, May 4th. They set an “overweight” rating and a $400.00 price target for the company. Jefferies Financial Group lowered shares of BeOne Medicines from a “buy” rating to a “hold” rating and cut their target price for the company from $420.00 to $290.00 in a report on Monday, March 16th. Finally, Truist Financial reaffirmed a “buy” rating and set a $413.00 target price (up from $411.00) on shares of BeOne Medicines in a report on Thursday, May 7th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $390.00.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.